In NSCLC, clear evidence of resistance to BRAF and MEK inhibitors are yet to be reported (61).Because cancers are virtually usually multiclonal and genetically heterogeneous, combination therapy is widely recommended. This evidence concerns the gene MAP2K7 and cancer.